PMCB
displays a very clear change in direction of trend following a basing process that includes a type specimen MACD Bullish Divergence. ------------------------------------
Pharmacyte Biotech Inc (OTCMKTS:PMCB)
Pharmacyte trumpets itself as a clinical stage biotechnology company that focuses on developing and commercializing cellular therapies for cancer and diabetes in the United States.
Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable non-metastatic pancreatic cancer, as well as diabetes.
The company is developing therapies for pancreatic and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the activation of cancer-killing drugs to the source of the cancer. It is also developing a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes; and therapies for cancer based on the constituents of the cannabis plant.